Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Testimonials
CCF Australia is a professional 'Patient-Centric' and 'Patient-Led' Organisation, [...]
Steven West: Cholangio Survivor
The opportunity to help other newly diagnosed patients help themselves, to understand in a manner that they can mount a robust and effective response is the reward
Lynette Williams: Cholangiocarcinoma Survivor
In order to successfully fight this disease we need to be armed with as much information as possible.
Lisa Salem-Craine: Cholangio Survivor
I met Steve and Claire Holmes many years ago and connected with them because like Steve, I am a cholangiocarcinoma survivor.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Testimonials
CCF Australia is a professional 'Patient-Centric' and 'Patient-Led' Organisation, [...]
Steven West: Cholangio Survivor
The opportunity to help other newly diagnosed patients help themselves, to understand in a manner that they can mount a robust and effective response is the reward
Lynette Williams: Cholangiocarcinoma Survivor
In order to successfully fight this disease we need to be armed with as much information as possible.
Lisa Salem-Craine: Cholangio Survivor
I met Steve and Claire Holmes many years ago and connected with them because like Steve, I am a cholangiocarcinoma survivor.
